iHuman Q2 Adj EPADS $0.06 Down From $0.11 YoY, Sales $29.60M Down From $33.23M YoY
Portfolio Pulse from Benzinga Newsdesk
iHuman reported a decrease in Q2 adjusted EPADS to $0.06 from $0.11 year-over-year, and a decline in sales to $29.60 million from $33.23 million year-over-year.
September 27, 2024 | 9:50 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
iHuman's Q2 financial results show a decline in both adjusted EPADS and sales compared to the previous year, indicating potential challenges in revenue generation.
The decrease in both adjusted EPADS and sales suggests financial underperformance, which could negatively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100